The mtor signaling pathway is an emerging therapeutic target in multiple myeloma

Current Pharmaceutical Design

Volumn 20, Issue 1, 2014, Pages 123-135

  Li, Jie ^a   Zhu, Jingyu ^a   Cao, Biyin ^a   Mao, Xinliang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Drug discovery; Mammalian target of rapamycin (mTOR); MTOR complex 1; MTOR complex 2; Multiple myeloma

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; 8 (6 METHOXY 3 PYRIDINYL) 3 METHYL 1 [4 (1 PIPERAZINYL) 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZO[4,5 C]QUINOLIN 2(3H) ONE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE; DACTOLISIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN; PROTEIN DEPTOR; PROTEIN KINASE B; SCAFFOLD PROTEIN; TEMSIROLIMUS; TORIN 1; UNCLASSIFIED DRUG; WYE 354; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BENDAMUSTINE; BORTEZOMIB; DEPTOR PROTEIN; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MELPHALAN; PANOBINOSTAT; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; RAPAMYCIN; RIDAFOROLIMUS; SAPANISERTIB; THALIDOMIDE; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; UBIQUITIN; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; COMPETITIVE INHIBITION; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; HUMAN; MULTIPLE MYELOMA; NEGATIVE FEEDBACK; NONHUMAN; PDZ DOMAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG EFFECT; METABOLISM; REVIEW; ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; KIDNEY CARCINOMA; PANCREAS CANCER; REGULATORY MECHANISM; SOLID TUMOR; TREATMENT RESPONSE; TUMOR INVASION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84894240917     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990638     Document Type: Article

References (96)

1. Mahindra A, Cirstea D, Raje N. Novel therapeutic targets for multiple myeloma. Future Oncol 2010; 6: 407-18.
2. Gera J, Lichtenstein A. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk Lymphoma 2011; 52: 1857-66.
3. Kozany C, Marz A, Kress C, et al. Fluorescent probes to characterise FK506-binding proteins. Chembiochem 2009; 10: 1402-10.
4. Chen G, Chen SM, Wang X, et al. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem 2012; 287: 12132-41.
5. Cafferkey R, McLaughlin MM, Young PR, et al. Yeast TOR (DRR) proteins: amino-acid sequence alignment and identification of structural motifs. Gene 1994; 141: 133-6.
6. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
7. Peterson RT, Desai BN, Hardwick JS, et al. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A 1999; 96: 4438-42.
8. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-7.
9. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
10. Ernstoff MS. mTOR Pathway and mTOR Inhibitors in Cancer Therapy. Br J Clin Pharmacol 2011; 71: 970.
11. Willems L, Tamburini J, Chapuis N, et al. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14: 129-38.
12. Fernandez-Saiz V, Targosz BS, Lemeer S, et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol 2013; 15: 72-81.
13. Kaizuka T, Hara T, Oshiro N, et al. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem 2010; 285: 20109-16.
14. Kim DH, Sarbassov DD, Ali SM, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrientsensitive interaction between raptor and mTOR. Mol Cell 2003; 11: 895-904.
15. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-75.
16. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003; 278: 15461-4.
17. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
18. Vander Haar E, Lee SI, Bandhakavi S, et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007; 9: 316-23.
19. Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 2006; 16: 1865-70.
20. Martin J, Masri J, Bernath A, et al. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun 2008; 372: 578-83.
21. Pearce LR, Sommer EM, Sakamoto K, et al. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J 2011; 436: 169-79.
22. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
23. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
24. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
25. Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci 2011; 12: 30-42.
26. Kawauchi K, Ogasawara T, Yasuyama M, et al. Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents Med Chem 2009; 9: 1024-38.
27. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25: 6436-46.
28. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010; 9: 3470-8.
29. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005; 12 Suppl 2: 1528-34.
30. Cea M, Cagnetta A, Fulciniti M, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012; 120: 3519-29.
31. Hosokawa N, Hara T, Kaizuka T, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009; 20: 1981-91.
32. Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-95.
33. Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer 2011; 31: 8-18.
34. Zaytseva YY, Valentino JD, Gulhati P, et al. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319: 1-7.
35. Mao X, Cao B, Wood TE, et al. A small-molecule inhibitor of Dcyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood 2011; 117: 1986-97.
36. Younes A, Samad N. Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011; 16: 730-41.
37. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010; 67: 2095-106.
38. Schenone S, Brullo C, Musumeci F, et al. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 2011; 18: 2995-3014.
39. Altomare DA, Khaled AR. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem 2012; 19: 3748-62.
40. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22: 169-76.
41. Strimpakos AS, Karapanagiotou EM, Saif MW, et al. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009; 35: 148-59.
42. Jozwiak J, Jozwiak S, Grzela T, et al. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med 2005; 7: 287-96.
43. Ellisen LW. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 2005; 4: 1500-02.
44. Proud CG. Dynamic balancing: DEPTOR tips the scales. J Mol Cell Biol 2009; 1: 61-3.
45. Zhang HR, Chen JM, Zeng ZY, et al. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res 2013; 41: 584-95.
46. Zhang H, Chen J, Zeng Z, et al. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. Int J Mol Med 2013; 31: 1127-34.
47. Cao B, Li J, Mao X. Dissecting bortezomib: development, application, adverse effects and future direction. Curr Pharm Des 2013; 19: 3190-200.
48. Cao B, Mao X. The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res 2011; 1: 46-56.
49. Fujii Y, Yada M, Nishiyama M, et al. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci 2006; 97: 729-36.
50. Abraham RT. Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again. F1000 Biol Rep 2009; 1: 8.
51. Menu E, van Valckenborgh E, van Camp B, et al. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115: 49-57.
52. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003; 4: 557-64.
53. Keats JJ, Reiman T, Belch AR, et al. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006; 47: 2289-300.
54. Montero JC, Lopez-Perez R, San Miguel JF, et al. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica 2008; 93: 851-9.
55. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587-97.
56. Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011; 118: 6860-70.
57. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23: 537-48.
58. Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116: 4560-8.
59. Boyd KD, Walker BA, Wardell CP, et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma 2010; 51: 2126-9.
60. Tagoug I, Plesa A, Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol 2013; 706: 11-6.
61. Que W, Chen J, Chuang M, et al. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Apmis 2012; 120: 195-203.
62. Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother 2002; 56: 115-28.
63. de la Rubia J, Such E. DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma? Leuk Lymphoma 2010; 51: 1960-1.
64. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984; 37: 1231-7.
65. Houchens DP, Ovejera AA, Riblet SM, et al. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 1983; 19: 799-805.
66. Liu Q, Thoreen C, Wang J, et al. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg 2009; 6: 47-55.
67. Baumann P, Schneider L, Mandl-Weber S, et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 2012; 23: 131-8.
68. Yang H, Rudge DG, Koos JD, et al. mTOR kinase structure, mechanism and regulation. Nature 2013; 497: 217-23.
69. Shi Y, Hsu JH, Hu L, et al. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 2002; 277: 15712-20.
70. Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via Pglycoprotein. J Clin Oncol 2011; 29: 3427-34.
71. Lu B, Li J, Pan J, et al. Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of proapoptotic and cell-cycle-progression regulatory proteins. Acta Biochim Biophys Sin (Shanghai) 2013.
72. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma 2009; 50: 1916-30.
73. Venugopal B, Ansari J, Aitchison M, et al. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol 2013; 13: 26.
74. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98: 10314-9.
75. Kelly KR, Rowe JH, Padmanabhan S, et al. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol 2011; 6: 53-61.
76. Lemoine M, Derenzini E, Buglio D, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012; 119: 4017-25.
77. Younes H, Leleu X, Hatjiharissi E, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007; 13: 3771-5.
78. Lamming DW, Ye L, Sabatini DM, et al. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013; 123: 980-9.
79. Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-80.
80. Roulin D, Cerantola Y, Dormond-Meuwly A, et al. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 2010; 9: 57.
81. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231-41.
82. Hoang B, Frost P, Shi YJ, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116: 4560-8.
83. Hoang B, Benavides A, Shi Y, et al. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signalregulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem 2012; 287: 21796-805.
84. Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011; 118: 6860-70.
85. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61.
86. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem 2009; 284: 8023-32.
87. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69: 6232-40.
88. Stengel C, Cheung CW, Quinn J, et al. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia 2012; 26: 1761-70.
89. Garcia-Martinez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009; 421: 29-42.
90. Collak FK, Yagiz K, Luthringer DJ, et al. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J Biol Chem 2012; 287: 23698-709.
91. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010; 16: 4914-20.
92. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics 2008; 7: 1851-63.
93. McMillin DW, Ooi M, Delmore J, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69: 5835-42.
94. Baumann P, Mandl-Weber S, Oduncu F, et al. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009; 315: 485-97.
95. Baumann P, Schneider L, Mandl-Weber S, et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti-Cancer Drugs 2012; 23: 131-8.
96. Glassford J, Kassen D, Quinn J, et al. Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations. Blood Cancer J 2012; 2: e50.